RNA-based therapeutics have shown great promise in various medical applications, including cancers, infectious diseases, and metabolic diseases. The recent success of mRNA vaccines for combating the COVID-19 pandemic has highlighted the medical value of RNA drugs. However, one of the major challenges in realizing the full potential of RNA drugs is to deliver RNA into specific organs and tissues in a targeted manner, which is crucial for achieving therapeutic efficacy, reducing side effects, and enhancing overall treatment efficacy. Numerous attempts have been made to pursue targeting, nonetheless, the lack of clear guideline and commonality elucidation has hindered the clinical translation of RNA drugs. In this review, we outline the mechanisms of action for targeted RNA delivery systems and summarize four key factors that influence the targeting delivery of RNA drugs. These factors include the category of vector materials, chemical structures of vectors, administration routes, and physicochemical properties of RNA vectors, and they all notably contribute to specific organ/tissue tropism. Furthermore, we provide an overview of the main RNA-based drugs that are currently in clinical trials, highlighting their design strategies and tissue tropism applications. This review will aid to understand the principles and mechanisms of targeted delivery systems, accelerating the development of future RNA drugs for different diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465230 | PMC |
| http://dx.doi.org/10.7150/thno.87316 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood-brain barrier crossing biopolymer activates immunity in primary brain lymphoma by targeting c-Myc and α-PD-1: Artificial intelligence analysis.
J Control Release
March 2025
Department of Molecular Pharmaceutics/CCCD, University of Utah, 20 S 2030 E, Salt Lake City, UT 84112, United States. Electronic address:
Primary Central Nervous System Lymphoma is an aggressive central nervous system neoplasm with poor response to pharmacological treatment, partially due to insufficient drug delivery across blood-brain barrier. In this study, we developed a novel therapy for this lymphoma by combining a targeted nanopolymer treatment with an immune checkpoint inhibitor antibody (anti-PD-1). A N-(2-hydroxypropyl)methacrylamide copolymer-based nanoconjugate was designed to block tumor cell c-Myc oncogene expression by antisense oligonucleotide.
View Article and Find Full Text PDFA new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model.
Eur J Med Chem
March 2025
Department of Pharmacy, "Drug Discovery" Laboratory, University of Napoli Federico II, 80131, Napoli, Italy. Electronic address:
A rational drug design approach led to the synthesis of three pairs of enantiomers derived from the peroxisome proliferator-activated receptor (PPAR) pan agonist AL29-26, identifying (S)-2 as a potent and selective PPARα partial agonist. Molecular docking and molecular dynamics simulations elucidated the binding modes of (S)-2 within the ligand-binding domains of PPARα and PPARγ. In vitro, (S)-2 demonstrated significant anti-steatotic effects, upregulating key PPARα target genes involved in lipid metabolism.
View Article and Find Full Text PDFFacilitating access to direct-acting antivirals in a community-based point-of-diagnosis model for hepatitis C treatment: The role of the pharmacy team in the no one waits (NOW) study.
Int J Drug Policy
March 2025
Department of Epidemiology and Biostatistics, UCSF, USA. Electronic address:
Background: Despite simplified hepatitis C virus (HCV) treatment algorithms, insurance-related barriers prevent same-day HCV treatment upon diagnosis in the US. We assessed how direct partnerships with a pharmacy team facilitated HCV treatment initiation among socially marginalized populations in a community setting.
Methods: The No One Waits (NOW) Study, a single-arm trial conducted between July 1, 2020, and October 31, 2021, in San Francisco, CA, targeted individuals experiencing homelessness, injecting drugs, and eligible for simplified HCV treatment.
Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.
J Viral Hepat
April 2025
Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany.
We analysed the frequency, severity and impact of hepatitis flares in a large Phase 2 study investigating pegylated interferon-alfa-2a (PEG-IFNa) for the treatment of hepatitis D. In the HIDIT-II study, 120 patients were treated for 96 weeks with PEG-IFNa (180 μg weekly) in combination with tenofovir disoproxil fumarate (TDF, 300 mg once daily) or placebo. Hepatitis flares were defined as ALT increases above 10 times the upper limit of normal or increases of more than 2.
View Article and Find Full Text PDFSpectroscopic, docking, antiproliferative, and anticancer activity of novel metal derivatives of phenylacetohydrazide Schiff base on different human cancer cell lines.
BMC Chem
March 2025
Chemistry Department, Faculty of Science, El-Fayoum University, El-Fayoum, Egypt.
In the last two decades, many Schiff bases have been investigated due to the importance of their metal complexes in the medical field and drug industry. The Schiff base metal complexes have several applications as anticancer agents because they have a high binding ability to nucleic acids (DNA and RNA). The Schiff base HL, derived from the condensation of 2-phenylacetohydrazide and 2-hydroxynaphthaldehyde, was reacted with Fe, Zn, Cd, and Pt to form the unique metal complexes [Fe(HL)], [Zn(HL)](CHCOO), [Cd(HL)](CHCOO), and [Pt(HL)Cl].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!